Mediana 32Q1: Consol. Revenue 16.1B, OP 1.61B, EPS 128 Won

Consolidated revenue 16.08B KRW (+7.3% YoY), operating profit 1.61B, net income 2.35B (vs 1.55B YoY), EPS 128 won
Cash & equivalents 26.64B, equity 138.19B, debt ratio 0% (no net debt)
Inventory 19.96B (up 44% from year-end 13.85B) → production expansion and proactive stockpiling
R&D expense 1.70B (10.17% of sales); ongoing development of core products (patient monitors, AEDs) and next-gen items (ACM10 CPR machine, unified monitoring solution)
New business: AI medical solutions expansion, launch of 'MEDICAL AI Strategic Alliance (MASA)'
Related-party transactions: sales to Selvas Healthcare 0.21B, purchases from Selvas AI 0.15B
Treasury shares 147,073 (0.79%); no dividend or share buyback in Q1